PTGX Stock: Price, Earnings History and SEC Filings
Protagonist Therapeutics, Inc. (PTGX) last traded at $144.85, up 0.35% on the latest session and up 2.8% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $2.29 against an analyst estimate of $2.11, a beat of 8.5%.
$144.85 +0.35%
1 month+2.81%
52-week high$160.81
52-week low$75.44
Volume322,566
ExchangeNasdaqGM
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
PTGX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 5, 2026 | $2.29 | $2.11 | +8.53% |
| Mar 2026 | May 5, 2026 | $0.05 | $-0.65 | +107.69% |
| Dec 2025 | Feb 25, 2026 | $-0.69 | $-0.53 | -30.19% |
| Sep 2025 | Nov 6, 2025 | $-0.62 | $-0.59 | -5.08% |
PTGX beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for PTGX
SEC filing data is not available right now. You can search for PTGX on SEC EDGAR.
PTGX news
- Protagonist Therapeutics (PTGX) to Report Q3 Results: Wall Street Expects Earnings GrowthOct 29, 2026 · finance.yahoo.com
- Wall Street Analysts See a 25.34% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High?Oct 28, 2026 · finance.yahoo.com
- Protagonist Therapeutics to Participate in Four Investment Bank Conferences in November 2026Oct 27, 2026 · finance.yahoo.com
- J&J Stock Reclaims 50-Day SMA: Is it Time to Buy, Sell or Hold?Oct 23, 2026 · finance.yahoo.com
- A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on MondayOct 20, 2026 · finance.yahoo.com
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. (PTGX) is a US-listed public company on Nasdaq.